Observational Study on Efficacy on Glycaemic Control of Slow-acting Insulin Analogue in Type 2 Diabetes

Novo Nordisk A/S1 site in 1 country2,745 target enrollmentJune 2007

ConditionsDiabetes Diabetes Mellitus, Type 2

Interventionsinsulin detemir

Drugsinsulin detemir

Overview

Phase: Not Applicable
Intervention: insulin detemir
Conditions: Diabetes
Sponsor: Novo Nordisk A/S
Enrollment: 2745
Locations: 1
Primary Endpoint: HbA1c
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This study is conducted in Europe. The aim of this observational study is to describe the conditions for the concomitant administration of a slow-acting insulin analogue with oral antidiabetics (OADs) in order to improve blood glucose control in type 2 diabetes.

Registry

clinicaltrials.gov

Start Date

June 2007

End Date

November 2008

Last Updated

9 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Novo Nordisk A/S

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Type 2 diabetes
•HbA1c level greater than 7% despite treatment with two (or three) oral antidiabetic drugs (OADs) at an optimal dose level
•Patient agreeing to take part in the study and capable of completing a self-questionnaire.

Exclusion Criteria

•Hypersensitivity to insulin or to one of the excipients
•Treatment with insulin for at least 6 months
•Participant in a clinical trial for diabetes on entry into the observational study